Floatz logo

dt2216

Recurrent Malignant Solid Neoplasm

Children's Oncology GroupSmall moleculePhase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

75 Active assets in the Recurrent Malignant Solid Neoplasm cohort.

Asset / SponsorPhaseRating
Cediranib
National Cancer Institute (NCI)
Phase 2BB
Crizotinib
M.D. Anderson Cancer Center
Phase 2B
Nivolumab
National Cancer Institute (NCI)
Phase 2B
Pembrolizumab
University of California, Davis
Phase 2B
Epirubicin
University of California, Davis
Phase 2B

View all 50 →

Same molecule, other indications

dt2216 is also rated in:

fibrolamellar hepatocellular carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
Recurrent Childhood Malignant Solid NeoplasmDormant
CCC
Indicative ·
48 / 100
View asset →
Refractory Childhood Malignant Solid NeoplasmDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →